Nolte D, Dusik B
Fortschr Med. 1983 Jul 7;101(25):1203-6.
In an open study with 306 hospitalized patients with obstructive airway diseases (149 males aged 57.2 +/- 13.0 years, 157 females aged 52.2 +/- 13.9 years), the tolerance of the new sustained-release theophylline preparation Uniphyllin was investigated. The duration of treatment was 3.1 +/- 1.3 weeks (males) or 2.9 +/- 1.2 weeks (females), respectively. For 75% of the male and 85% of the female patients a single evening dosage was sufficient. The number of side effects necessitating discontinuance of the theophylline therapy in females was three times that observed in males. Altogether, the 7.8% drop-out rate was very low, considering the seriously ill patients participating in the study. Accordingly, the new sustained-release theophylline preparation has been tolerated particularly well.
在一项针对306例住院阻塞性气道疾病患者的开放性研究中（149例男性，年龄57.2±13.0岁；157例女性，年龄52.2±13.9岁），对新型缓释茶碱制剂优喘平的耐受性进行了研究。治疗持续时间分别为男性3.1±1.3周、女性2.9±1.2周。75%的男性患者和85%的女性患者每晚单次给药即可。因副作用而必须停用茶碱治疗的女性患者数量是男性患者的三倍。考虑到参与研究的患者病情严重，总体7.8%的退出率非常低。因此，新型缓释茶碱制剂的耐受性特别好。
